BOSTON (Reuters) - William Ackman plans to communicate with other Allergan (AGN.N) shareholders after the Botox maker on Monday rebuffed a bid to be bought by the billionaire investor and Valeant Pharmaceuticals (VRX.TO).
In a regulatory filing on Monday, Ackman's hedge fund Pershing Square Capital Management said that it has requested a complete list of holders of record in Allergan to be able to "communicate with fellow stockholders of the company."
Ackman wrote to Allergan Associate General Counsel Matthew Maletta and asked that the company turn over the list within five business days. Institutional investors The Vanguard Group, State Street Global Advisors and BlackRock are also among the top 10 holders of Allergan stock, according to ThomsonReuters data.
Other hedge fund owners of Allergan include Visium Asset Management and Viking Global Investors, the data show.
Valeant and Pershing Square, which has a stake of almost 10 percent in Allergan, made an unsolicited cash and stock offer for the company in April.
(Reporting by Svea Herbst-Bayliss, editing by Richard Valdmanis and Cynthia Osterman)
- Financials Industry
- Private Equity & Hedge Funds
- William Ackman
- Valeant Pharmaceuticals